Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) | RFA TR 22 011

Opportunity Information: Apply for RFA TR 22 011

This grant opportunity, titled "Emergency Awards: HEAL Initiative - Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)" (RFA-TR-22-011), is a National Institutes of Health (NIH) funding announcement issued by the National Center for Advancing Translational Sciences (NCATS) in direct response to the federally declared public health emergency related to the opioid crisis. It sits under the broader NIH Helping to End Addiction Long Term (HEAL) Initiative, which is designed to speed up scientific progress toward better prevention and treatment options across the opioid addiction cycle, including chronic use, withdrawal, craving, relapse, and overdose. The central idea behind this specific FOA is to catalyze earlier, discovery-oriented work that can open up brand-new biological directions for medication development, rather than simply extending well-studied targets that already dominate the drug development landscape.

The focus of the program is the identification of new "druggable" targets for pain, opioid use disorder (OUD), and/or opioid overdose, specifically within the "understudied druggable proteome." In practical terms, this means the research is expected to concentrate on proteins (and related biological targets) that are believed to be modifiable with therapeutic agents but have not historically received much attention from the biomedical research or pharmaceutical communities. By pushing investigators toward less-explored parts of the proteome, the FOA aims to expand the pipeline of plausible targets that could eventually be translated into non-addictive pain therapeutics, improved medications for OUD, and potentially interventions that reduce overdose risk or severity. The projects supported are early-stage by design, meaning they are meant to generate compelling initial evidence, reveal tractable mechanisms, and provide a foundation for later-stage validation and therapeutic development.

The award mechanism is an NIH R21, which is commonly used for exploratory and developmental research. As stated in the title, clinical trials are not allowed under this announcement, so the supported work is intended to remain on the discovery and preclinical side rather than testing interventions in human participants. The overall funding instrument is a grant, and the opportunity is categorized as discretionary funding within the broad activity areas of education and health. The opportunity also links to multiple CFDA (now commonly referred to as Assistance Listing) numbers, reflecting the cross-cutting relevance of the work to multiple NIH program areas, including translational science and drug discovery related portfolios.

In terms of who can apply, eligibility is broad across U.S.-based organizations and spans government, academia, nonprofit, and private-sector entities. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not higher education institutions in those categories); for-profit organizations (other than small businesses); small businesses; and other eligible entities. The FOA explicitly highlights additional eligible applicant types that NIH is encouraging to participate, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain tribal governments other than federally recognized ones. At the same time, the FOA places clear limits on foreign involvement: non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by NIH policy are not allowed. In effect, applicants need to ensure the proposed work is carried out entirely within allowable domestic institutional structures.

The funding details provided indicate an award ceiling of $275,000, and the original application due date listed is April 17, 2023, with the FOA having been created on January 20, 2022. While the expected number of awards is not specified in the provided data, the structure and emergency framing signal that NIH intended this as a targeted push to stimulate rapid, high-value exploration of novel targets aligned with the HEAL mission. Overall, the opportunity is best understood as a time-sensitive, discovery-driven investment aimed at expanding the range of viable biological targets for treating pain and opioid-related conditions, with an emphasis on overlooked parts of the human proteome that could yield fresh therapeutic strategies.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.350, 93.393, 93.846, 93.853, 93.866.
• This funding opportunity was created on 2022-01-20.
• Applicants must submit their applications by 2023-04-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $275,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA TR 22 011

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: